AEHR Insiders Cashed Out $25.9M After Years of Shareholder Dilution

Heavy insider selling, repeated dilution, and weakening fundamentals raise serious questions about shareholder alignment

Aehr Test Systems (NASDAQ: AEHR) has often been presented as a high-growth semiconductor equipment story tied to silicon carbide, EV power devices, and emerging AI infrastructure demand. But behind the narrative lies a more uncomfortable reality for shareholders: years of dilution followed by a major insider cash-out during a sharp stock rally.

According to SEC Form 4 filings, AEHR insiders sold approximately 355,105 shares during April 2026 for an estimated gross value of $25.9 million in roughly 20 trading days.

That figure is notable because it is broadly equivalent to the company’s entire cumulative EBITDA over the last five fiscal years, estimated at roughly $25.4 million.

In plain English: insiders monetized in one month what the business generated in operating earnings over half a decade.

Years of Dilution Before the Cash-Out

While insiders were later able to sell into strength, long-term shareholders first endured substantial dilution.

AEHR’s shares outstanding rose from approximately 23.7 million at the end of FY2021 to roughly 29.9 million by FY2025.

That represents an increase of around 26% in the share count over just four years.

For existing shareholders who did not add capital along the way, ownership percentages were steadily diluted.

Sources of Dilution Included:

• Public equity offerings
• Employee stock plans
• Stock-based compensation
• Option exercises
• Shares issued in acquisitions

Major Capital Raises Included:

• FY2022: meaningful public offering raising fresh capital
• FY2023: additional smaller offering
• Ongoing employee-related issuance thereafter

This means investors were asked to accept dilution during the growth phase—only to watch insiders later sell aggressively into a rally.

Then Came the April 2026 Insider Exit Wave

This was not one executive making a routine sale. It involved a broad group of insiders, including top leadership.

Largest Sellers

The top two insiders alone accounted for more than $15 million in proceeds.

Not Routine Scheduled Selling

Based on reviewed filings, the majority of these April transactions do not appear to have been executed under Rule 10b5-1 pre-arranged trading plans.

That suggests many sales were discretionary decisions rather than passive automated selling.

For investors, that distinction matters.

Selling because a trading plan triggers is one thing. Choosing to sell large amounts during a speculative rally is another.

Selling Into a Vertical Rally

The timing was ideal—from an insider’s perspective.

AEHR shares surged from approximately $37 in late March to nearly $100 in April 2026.

That kind of move creates exceptional liquidity and elevated valuations. It also creates an ideal exit window for insiders holding low-cost stock grants, options, or shares accumulated over prior years.

Retail investors chasing momentum may have been providing the liquidity insiders used to cash out.

Meanwhile, the Business Was Losing Momentum

While the stock surged, the operating business had already begun to cool.

Revenue History

• FY2021: $16.6M
• FY2022: $50.8M
• FY2023: $65.0M
• FY2024: $66.2M
• FY2025: $59.0M

After a rapid growth phase, revenue declined in FY2025.

Based on reconstructed figures from filings, EBITDA also turned negative again in FY2025.

So shareholders faced:

• dilution over multiple years,
• slowing fundamentals,
• and then a major insider selling wave.

The Alignment Problem

This sequence creates a difficult question for investors:

If shareholders accepted dilution to finance growth, why were insiders the ones monetizing so heavily once the stock spiked?

A healthy shareholder-aligned cycle would ideally look like:

1. Raise capital prudently
2. Grow per-share value
3. Deliver sustained profitability
4. Limit dilution
5. Insiders retain meaningful upside exposure

Instead, AEHR shareholders saw:

1. Rising share count
2. Volatile earnings
3. Revenue slowdown
4. Heavy insider selling into strength

What Investors Should Consider

None of this proves misconduct. Insider selling can be legal and rational.

But legal does not always mean shareholder-friendly.

When insiders sell amounts comparable to five years of EBITDA after shareholders have absorbed years of dilution, investors should ask whether management’s incentives are truly aligned with outside owners.

Bottom Line

AEHR may still have attractive technology and exposure to semiconductor growth markets. But the capital allocation record deserves as much scrutiny as the product story.

For shareholders, the real story may not be burn-in systems or AI demand.

It may be this:

They absorbed the dilution. Insiders captured the rally.

Disclaimer

This article is based on public filings and financial statements. It is opinion commentary, not investment advice.